共 50 条
Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy
被引:6
|作者:
Kondo, Yasuteru
[1
]
Ueno, Yoshiyuki
[1
]
Ninomiya, Masashi
[1
]
Tamai, Keiichi
[1
]
Tanaka, Yasuhito
[2
]
Inoue, Jun
[1
]
Kakazu, Eiji
[1
]
Kobayashi, Koju
Kimura, Osamu
[1
]
Miura, Masahito
[3
]
Yamamoto, Takeshi
[4
]
Kobayashi, Tomoo
[5
]
Igarashi, Takehiko
[6
]
Shimosegawa, Tooru
[1
]
机构:
[1] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 980, Japan
[2] Nagoya City Univ, Sch Med, Virol & Liver Unit, Nagoya, Aichi 467, Japan
[3] S Miyagi Med Ctr, Dept Gastroenterol, Oogawara, Miyagi, Japan
[4] Tohoku Kosei Nenkin Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan
[5] Tohoku Rosai Hosp, Dept Hepatol, Sendai, Miyagi, Japan
[6] Osaki Citizen Hosp, Dept Gastroenterol, Osaki, Japan
关键词:
Dual infection;
HBV;
HCV;
Immunopathogenesis;
HEPATITIS-B-VIRUS;
REGULATORY T-CELLS;
HEPATOCELLULAR-CARCINOMA;
COINFECTED PATIENTS;
DUAL INFECTION;
GENOTYPE-B;
VIRAL INTERACTIONS;
IMMUNE-RESPONSES;
INTERFERON;
RIBAVIRIN;
D O I:
10.1007/s00535-012-0596-x
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-gamma-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-gamma-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-gamma-secreting cells were also increased during Peg-IFN/RBV-therapy. The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.
引用
收藏
页码:1323 / 1335
页数:13
相关论文